Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=78527&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation (AVXL)

LOS ANGELES , May 7, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ: AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 13, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=78469&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL

NEW YORK , May 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL). Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

LOS ANGELES , May 6, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ). Class Period: February 1, 2022 – January 1, 2024 Lead Plaintiff Deadline: May 13, 2024 If you wish to serve as lead plaintiff of the Anavex lawsuit, you can submit your contact information at www.glancylaw.com/cases/Anavex-Life-Sciences-Corp-1/.

AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / May 6, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=78266&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Anavex Life Sciences Corporation (AVXL) should contact Levi & Korsinsky about pending Class Action - AVXL

NEW YORK, NY / ACCESSWIRE / May 5, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=78192&wire=1 or contact Joseph E. Levi, Esq.

May 13, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against AVXL

NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corporation ("Anavex" or the "Company") (NASDAQ: AVXL) and reminds investors of the May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Anavex stock or options between February 1, 2022 and January 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

NEW YORK , May 3, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL). Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL

NEW YORK, NY / ACCESSWIRE / May 2, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=77910&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Anavex Life Sciences Corporation Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL

Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ET Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ET

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=77644&wire=1 or contact Joseph E. Levi, Esq.

Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights – AVXL

NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=77606&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders

NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL

NEW YORK , April 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL). Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL

NEW YORK, NY / ACCESSWIRE / April 26, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=77121&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of Anavex Life Sciences Corporation (AVXL) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=77001&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation (AVXL) Shareholders

NEW YORK , April 25, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corporation ("Anavex" or the "Company") (NASDAQ: AVXL) and reminds investors of the May 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Anavex To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Anavex stock or options between February 1, 2022 and January 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76878&wire=1 or contact Joseph E. Levi, Esq.

Investors Who Lost Money on Anavex Life Sciences Corporation (AVXL) Should Contact Levi & Korsinsky About Pending Class Action - AVXL

NEW YORK, NY / ACCESSWIRE / April 24, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76874&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join – Contact Levi & Korsinsky

NEW YORK , April 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL). Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL)

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=76066&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on Anavex Life Sciences Corporation(AVXL) Should Contact Levi & Korsinsky about Pending Class Action - AVXL

NEW YORK, NY / ACCESSWIRE / April 17, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/anavex-life-sciences-lawsuit-submission-form?prid=75984&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Anavex Life Sciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 – AVXL

NEW YORK , April 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL). Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL

LOS ANGELES, CA / ACCESSWIRE / April 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ:AVXL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 1, 2022 and January 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 13, 2024.

News for Anavex Life Sciences Stock (AVXL)